Bruxism is repetitive clenching or grinding of the teeth, driven by jaw muscle activity that occurs during sleep, while awake, or both — often without the person being aware it is happening. Common associated findings include jaw or facial muscle soreness, temporal headache, and tooth wear or chipping identified on dental examination.
These figures come from a single 3-year restorative trial in which bruxism status was confirmed by questionnaire and portable EMG rather than polysomnography, and the protocol did not permit guard use; see “Which Treatment Is Right for Me?” below for context.
Key Points
- Bruxism has two clinically distinct forms — sleep bruxism and awake bruxism — with different drivers and different management approaches.
- Self-reported prevalence estimates vary by population, from roughly one-third to 40% depending on the sample studied (e.g., dental student cohorts vs. general-population cohorts), and bruxism is significantly associated with temporomandibular disorders (TMD).
- Diagnosis is mainly clinical; when objective confirmation is needed, polysomnography with concurrent audio/video recording and EMG is the reference standard for a “definite” diagnosis under current consensus grading criteria.
- Standard first-line treatment is an occlusal splint (night guard), used primarily to protect the teeth and restorations; manual therapy, botulinum toxin (an off-label use in most jurisdictions), and treatment of an underlying cause are options in select cases.
- Bruxism can be secondary to another condition — such as sleep-disordered breathing or pain from elsewhere in the jaw — so identifying the driver matters as much as treating the symptom.
What Is Bruxism?
Bruxism refers to repetitive jaw-muscle activity — clenching, grinding, or bracing the teeth together — that is not part of normal chewing or speech. Sleep bruxism occurs during sleep and is classified as a sleep-related movement disorder. Awake bruxism occurs during wakefulness and is more often linked to concentration, stress, or habit.
Over time, sustained occlusal force from bruxism can produce measurable tissue effects, including enamel and dentin wear and changes in periodontal sensation and tooth position. Evidence for an effect on mandibular bone morphology comes from a single radiographic comparison of treated, untreated, and healthy individuals in the context of a botulinum toxin type A study; the imaging method (panoramic radiography) is subject to distortion and superimposition, and bone findings were not correlated with symptoms [PMID 41781316]. This should be regarded as a preliminary observation rather than an established general effect of bruxism on bone. Bruxism is also significantly associated with TMD: a large Finnish birth cohort study (n=1,962) found a 39.6% prevalence of self-reported bruxism (34.0% in men, 44.5% in women), with a statistically significant link to TMD symptoms and diagnoses.
A separate and more tentative line of discussion concerns a possible relationship between sleep bruxism and airway physiology. One narrative review, discussing findings from a mandibular advancement device (MAD) trial, described a reduction in bruxism scores as probably related to resolution of breathing events, and noted that bruxism has been considered a protective muscular response in that context — while also citing other authors reporting conflicting findings. This is a hedged observation drawn from a single trial’s secondary finding, not an established mechanism, and results across studies in this area are mixed. It should not be read as evidence that sleep bruxism is generally secondary to airway obstruction; in most patients, the relationship between bruxism and airway status has not been established.
How Common Is It?
Prevalence estimates vary by population and how bruxism is measured. In a cross-sectional study of Thai dental students (n=464, mean age 21.4), self-reported awake bruxism was 35.78% and sleep bruxism was 37.28%, with 19.40% reporting both; this sample is younger and more topic-aware than the general adult population and should not be generalized without qualification. In a larger, general-population Finnish birth cohort (n=1,962), self-reported bruxism prevalence was 39.6%. Because most of these figures rely on self-report rather than objective monitoring, they likely both over- and under-capture true rates — patients aren’t always aware of nighttime grinding, and daytime clenching can go unnoticed until symptoms appear.
Bruxism prevalence also varies substantially by clinical population. In children and adolescents with Down syndrome, a cluster analysis found sleep bruxism in 5% of children versus 46% of adolescents, with the highest-frequency group characterized by concurrent reflux, snoring, antidepressant use, shortened sleep duration, and elevated screen time [PMID 42464691]. This illustrates that bruxism is frequently multifactorial rather than an isolated habit, particularly in medically complex patients.
How Is It Diagnosed?
Diagnosis usually starts with a clinical exam: patterns of tooth wear, muscle tenderness on palpation, jaw muscle hypertrophy, and mouth-opening range. A history from the patient — or a bed partner, for sleep bruxism — adds useful information, though awareness of bruxism and its effects differs notably between clinicians and patients; one survey found awareness scores were significantly higher among dentists than patients (p<0.001).
When objective confirmation is needed — for example, to rule out or evaluate for co-occurring sleep-disordered breathing — polysomnography with concurrent audio/video recording and EMG is the reference standard for a “definite” diagnosis under current consensus grading criteria (possible/probable/definite). Polysomnographic studies show that the number of bruxism episodes and bruxism index correlate strongly with visible tooth abrasion severity (p<0.001). However, tooth wear is cumulative and reflects lifetime occlusal load, diet, and erosive exposure in addition to bruxism activity; it is not accepted in consensus diagnostic criteria as a reliable standalone marker of current or active sleep bruxism. Tooth wear findings are best interpreted as supportive evidence alongside clinical exam and, where indicated, objective monitoring — not as a substitute for either.
Which Treatment Is Right for Me?
Treatment choice depends on symptom severity, whether the bruxism is primary or secondary to another condition, and treatment goals (pain relief, protecting the teeth, or both).
| Option | What the evidence shows | Best suited to |
|---|---|---|
| Occlusal splint (night guard) | Standard first-line approach for protecting teeth and restorations from wear; evidence that splints reduce jaw muscle activity or “strain” is inconsistent. Long-term adherence varies — in a survey of Thai dental students who self-identified as sleep bruxers, only 12.14% reported still wearing a night guard long-term | Most patients with tooth wear or muscle symptoms |
| Manual therapy (myofascial release / post-isometric relaxation) | Single-session double-blind RCT (n=60): myofascial release reduced pain (p=.010) and masseter muscle stiffness (p=.030) more than control; effects measured immediately only, not over time [PMID 41414918] | Adjunct for muscle pain and stiffness; durability of benefit not yet established |
| Botulinum toxin type A | 6-month radiographic study (n=60): associated with fewer higher-grade mandibular bone changes and greater cortical thickness compared with untreated bruxism patients; correlation with symptom improvement was not assessed [PMID 41781316]. Use for bruxism/masticatory muscle hyperactivity is off-label in most jurisdictions | Select cases under specialist supervision, with discussion of off-label status |
| Restorative material choice (crowns) | 3-year RCT (n=109): no statistically significant difference in survival between lithium disilicate and zirconia crowns in bruxers vs. non-bruxers; the trial did not permit guard use, which departs from typical protective protocol, and bruxism status was confirmed by questionnaire/portable EMG rather than PSG [PMID 41967567] | Restorative planning discussions with your treating dentist |
| Treating an underlying driver | Case report (n=1, no control group): describes bruxism developing secondary to pain-driven clenching related to mandibular osteomyelitis, with symptom resolution after the underlying condition and splint therapy were both addressed; the relative contribution of each cannot be determined from a single case [PMID 42394563] | Patients with suspected sleep apnea or an identifiable pain source elsewhere in the jaw, as one illustrative example among possible underlying drivers |
A splint remains the standard first step for most patients. Manual therapy and botulinum toxin are better understood as adjuncts, with evidence still limited to short observation windows and, for botulinum toxin, off-label status. If bruxism appears secondary to sleep-disordered breathing or another pain condition, addressing that underlying driver is typically part of a complete plan.
When to See a Specialist
Consider an orofacial pain or dental sleep medicine evaluation if you have persistent jaw or facial muscle pain, restricted mouth opening, headaches concentrated at the temples, significant or accelerating tooth wear, or bruxism that isn’t improving with a standard night guard. Snoring, witnessed pauses in breathing, or unrefreshing sleep alongside bruxism warrant screening for sleep-disordered breathing, since treating an underlying airway problem may be more effective than treating the bruxism in isolation.
For Referring Providers
Current evidence on adjunctive bruxism therapies is preliminary. The myofascial release/PIR trial demonstrates single-session effects on muscle stiffness and pain but does not establish treatment frequency or durability [PMID 41414918]. Radiographic BoNT-A findings suggest attenuated pathological bone remodeling but were not correlated with symptom outcomes, used panoramic imaging with known morphometric limitations, and derive from a single study; use of BoNT-A for masticatory muscle hyperactivity remains off-label in most jurisdictions [PMID 41781316]. The crown-survival trial supports material-agnostic restorative planning at 3 years but excluded guard use and confirmed bruxism status by questionnaire/portable EMG rather than PSG, limiting extrapolation to guard-protected, PSG-confirmed patients [PMID 41967567]. In medically complex pediatric populations (e.g., Down syndrome), bruxism frequently clusters with reflux, sleep fragmentation, and pharmacologic exposures, supporting a multidisciplinary rather than isolated dental workup [PMID 42464691]. When bruxism appears secondary to another structural or pain condition, treating the primary pathology alongside splint therapy may resolve the secondary muscular symptoms, as illustrated in a single case of clenching secondary to mandibular osteomyelitis; this is anecdotal (n=1) evidence and should not be generalized without corroborating studies [PMID 42394563]. Regarding the proposed link between sleep bruxism and airway physiology, the supporting observation derives from a single MAD trial discussed within a narrative review and is explicitly contested by other reported findings; it should not be presented to patients as an established mechanism.
References
- PMID 41414918 — Immediate effects of myofascial release and post-isometric relaxation on muscle properties and pain in symptomatic bruxism: A randomized, controlled, double-blind trial. Cranio, 2026.
- PMID 41781316 — Impact of botulinum toxin type A on mandibular bone parameters in bruxism: radiographic evidence from treated, untreated, and healthy individuals. Oral Surg Oral Med Oral Pathol Oral Radiol, 2026.
- PMID 41967567 — Ceramic crowns and sleep bruxism: 3-year results of a randomized controlled trial. J Dent, 2026.
- PMID 42464691 — Sleep Bruxism, Pharmacotherapy, Sleep Aspects and Screen Use in Children and Adolescents With Down Syndrome: A Cluster Analysis. J Appl Res Intellect Disabil, 2026.
- PMID 42394563 — Application of splint to relieve masticatory muscle symptoms caused by clenching in a mandibular osteomyelitis patient. Zhonghua Kou Qiang Yi Xue Za Zhi, 2026.
